Profile data is unavailable for this security.
About the company
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
- Revenue in SEK (TTM)1.90m
- Net income in SEK-5.65m
- Incorporated2006
- Employees8.00
- LocationKarolinska Development ABTomtebodavagen 23 ASOLNA 171 65SwedenSWE
- Phone+46 852486070
- Websitehttps://www.karolinskadevelopment.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bactiquant A/S | 13.66m | -22.02m | 178.64m | -- | -- | 17.20 | -- | 13.08 | -0.6558 | -0.6558 | 0.4064 | 0.2906 | 0.5101 | 2.94 | 5.06 | -- | -82.23 | -41.26 | -92.65 | -47.16 | -24.34 | 12.89 | -161.20 | -71.77 | 2.73 | -9.48 | 0.5326 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Neola Medical AB | 0.00 | -9.47m | 185.20m | 7.00 | -- | 2.51 | -- | -- | -0.1508 | -0.1508 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -12.63 | -17.04 | -13.59 | -18.46 | -- | 4,237.20 | -- | -5,258.78 | -- | -- | 0.00 | -- | -- | -- | 12.97 | -- | 55.46 | -- |
| Arcoma AB | 175.30m | 12.66m | 196.46m | 31.00 | 15.52 | 3.48 | 9.83 | 1.12 | 0.9598 | 0.9598 | 13.30 | 4.28 | 2.02 | 3.96 | 9.19 | 5,654,936.00 | 14.61 | 1.12 | 24.24 | 2.01 | 37.85 | 37.66 | 7.22 | 0.7568 | 1.25 | 18.83 | 0.0407 | 0.00 | 30.36 | 6.41 | 34.81 | -- | 22.75 | -- |
| Nanexa AB | 26.91m | -66.68m | 217.11m | 19.00 | -- | 2.50 | -- | 8.07 | -0.6938 | -0.6938 | 0.2484 | 0.6411 | 0.2108 | -3.83 | 2.99 | 1,416,316.00 | -52.24 | -40.77 | -70.59 | -48.77 | 118.77 | 77.27 | -247.79 | -532.26 | 1.92 | -- | 0.0174 | -- | 925.42 | 147.00 | -30.44 | -- | 39.10 | -- |
| SpectraCure AB (publ) | 2.36m | -21.18m | 222.43m | 13.00 | -- | 1.89 | -- | 94.09 | -0.218 | -0.218 | 0.0243 | 1.21 | 0.0166 | -- | 24.63 | 157,600.00 | -14.82 | -12.75 | -15.91 | -13.62 | 442.39 | 195.30 | -895.85 | -494.40 | -- | -- | 0.0494 | -- | -3.30 | -- | 19.46 | -- | -- | -- |
| Scandinavian Medical Solutions A/S | 300.32m | 8.17m | 270.14m | 25.00 | 32.90 | 2.30 | 14.66 | 0.8995 | 0.1963 | 0.1963 | 7.22 | 2.81 | 1.38 | 1.89 | 11.35 | -- | 3.75 | -- | 6.15 | -- | 24.48 | -- | 2.72 | -- | 0.4307 | 5.54 | 0.3473 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
| Nexstim Oyj | 89.82m | -9.45m | 285.46m | 39.00 | -- | 13.48 | -- | 3.18 | -0.1223 | -0.1223 | 1.19 | 0.2761 | 0.8196 | 0.2223 | 5.28 | 214,040.30 | -8.62 | -26.77 | -14.02 | -43.90 | 97.24 | 92.11 | -10.52 | -38.38 | 1.24 | -5.51 | 0.7716 | -- | -23.94 | 22.08 | -201.58 | -- | 19.51 | -- |
| Micropos Medical AB (publ) | 2.68m | -22.68m | 305.25m | 9.00 | -- | 14.92 | -- | 113.86 | -0.2463 | -0.2463 | 0.022 | 0.1341 | 0.0994 | 0.1315 | 1.20 | 335,122.50 | -84.10 | -64.24 | -111.33 | -82.27 | 79.96 | 114.76 | -845.91 | -767.57 | 3.18 | -- | 0.0184 | -- | 50.23 | 5.94 | -26.57 | -- | -- | -- |
| INIFY Laboratories AB | 3.44m | -51.69m | 306.07m | 23.00 | -- | 4.16 | -- | 88.99 | -1.18 | -1.18 | 0.0785 | 1.68 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Ortoma AB | 43.22m | -30.78m | 322.32m | 7.00 | -- | 1.95 | -- | 7.46 | -0.8112 | -0.8112 | 1.24 | 4.67 | 0.2294 | 1.01 | 4.49 | 6,173,962.00 | -16.34 | -10.45 | -17.53 | -11.64 | 86.83 | 339.86 | -71.22 | -175.52 | 3.04 | -- | 0.00 | -- | -- | -- | -38.87 | -- | 14.14 | -- |
| Acarix AB | 6.26m | -70.95m | 326.01m | 9.00 | -- | 4.81 | -- | 52.10 | -0.1168 | -0.1168 | 0.0095 | 0.0697 | 0.0894 | 0.1172 | 2.47 | -- | -101.38 | -66.93 | -123.43 | -77.12 | 88.27 | 79.42 | -1,133.87 | -1,483.68 | 5.21 | -328.98 | 0.00 | -- | 7.20 | 43.55 | -1.11 | -- | -- | -- |
| Karolinska Development AB | 1.90m | -5.65m | 337.08m | 8.00 | -- | 0.2762 | -- | 177.13 | -0.0209 | -0.0209 | 0.007 | 4.56 | 0.0015 | -- | 1.38 | 237,875.00 | -0.4536 | 3.37 | -0.4578 | 3.83 | -- | -- | -296.85 | 1,466.36 | -- | -- | 0.0021 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
| Boule Diagnostics AB | 572.53m | 21.28m | 338.62m | 230.00 | 16.24 | 0.6824 | 7.14 | 0.5915 | 0.5368 | 0.5368 | 14.45 | 12.78 | 0.724 | 4.19 | 3.69 | 2,511,092.00 | 2.68 | 1.67 | 3.71 | 2.40 | 43.86 | 43.50 | 3.70 | 2.04 | 0.9268 | 4.72 | 0.2698 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
| Q linea AB | 4.70m | -224.61m | 362.04m | 99.00 | -- | 5.32 | -- | 77.11 | -2.06 | -2.06 | 0.0428 | 0.5813 | 0.0277 | 0.1707 | 11.86 | 36,968.50 | -132.70 | -59.66 | -356.93 | -66.14 | -56.25 | -378.58 | -4,783.96 | -4,046.97 | 0.6999 | -- | 0.4555 | -- | -65.28 | 33.02 | 14.64 | -- | 41.94 | -- |
| ContextVision AB | 133.06m | 25.82m | 430.74m | 41.00 | 16.68 | 4.77 | 12.45 | 3.24 | 0.3445 | 0.3445 | 1.78 | 1.21 | 1.21 | 2.33 | 4.81 | 3,433,738.00 | 23.39 | 29.39 | 30.67 | 43.27 | 97.39 | 98.58 | 19.40 | 27.15 | 3.99 | -- | 0.0304 | -- | 12.19 | 7.78 | -1.77 | -- | -35.88 | -- |
| BrainCool AB (publ) | 32.23m | -57.17m | 483.47m | 20.00 | -- | 2.92 | -- | 15.00 | -0.2685 | -0.2685 | 0.1501 | 0.6527 | 0.2253 | 2.04 | 2.85 | 1,343,042.00 | -39.96 | -47.14 | -44.79 | -70.16 | -37.24 | -149.77 | -177.38 | -391.45 | 4.16 | -6.19 | 0.00 | -- | 32.06 | 78.35 | -34.34 | -- | -11.63 | -- |
Data as of Sep 19 2024. Currency figures normalised to Karolinska Development AB's reporting currency: Swedish Krona SEK
5.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 30 Aug 2024 | 8.75m | 3.27% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 1.50m | 0.56% |
| Skandia Investment Management ABas of 31 Jul 2024 | 1.13m | 0.42% |
| SEB Investment Management ABas of 30 Aug 2024 | 1.06m | 0.40% |
| FCG Fonder ABas of 30 Aug 2024 | 898.22k | 0.34% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 249.49k | 0.09% |
| Equinor Asset Management ASAas of 31 Dec 2023 | 54.30k | 0.02% |
| Skandia Fonder ABas of 31 Jul 2024 | 43.90k | 0.02% |
More ▼
Data from 31 Dec 2023 - 30 Aug 2024Source: FactSet Research Systems Inc.
